

## ASX Release

# Anatara Investor Presentation

BRISBANE, 21st June 2017: Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation for the Gold Coast Investment Showcase (June 21<sup>st</sup> & 22<sup>nd</sup> 2017).

A copy of the presentation is attached.

**For more information please contact:**

<b>General inquiries</b> Dr Mel Bridges Chairman & CEO Anatara Lifesciences +61 (0) 413 051 600 <a href="mailto:mbridges@anataralifesciences.com">mbridges@anataralifesciences.com</a>	<b>Media inquiries</b> Jane Lowe Managing Director IR Department +61 (0) 411 117 774 <a href="mailto:jane.lowe@irdepartment.com.au">jane.lowe@irdepartment.com.au</a>
---	--

### About Anatara Lifesciences

Anatara Lifesciences is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach™ is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.





ANATARA  
LIFESCIENCES

# Natural Alternative to Antibiotics

June 2017



# Disclaimer

*The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anantara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.*

*Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.*

*Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.*

*Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.*

*Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.*



# Key Financial Details

<b>ASX Code</b> <b>ANR</b>	<b>Market Capitalisation</b> <b>\$50.9 million</b>	<b>Share Price<sup>1</sup></b> <b>\$1.03</b>
<b>Current Cash<sup>2</sup></b> <b>\$11 million</b>	<b>Ordinary Shares</b> <b>49,413,236</b>	<b>Share Price</b> <b>up 142%</b> <b>since IPO</b>

1. As at 15 June 2017

2. Appendix 4C - 31 March 2017



# ANR Share Price Chart



# *Oral therapeutics for gastrointestinal disease in livestock and humans*

## Detach™

- Natural, safe, non-antibiotic therapeutic that prevents and treats gastrointestinal diseases, including diarrhoea
- Meets the need to reduce the use of antibiotics and zinc oxide in animal production
- Unlike antibiotics and zinc oxide, Detach™ will not contribute to antimicrobial resistance (AMR)



# Need to combat antimicrobial resistance

resistance to antibiotics ‘....*the greatest and most urgent global risk*’

General Assembly of the United Nations 2016


*Antibiotic resistance driven by the overuse of antibiotics in humans and agriculture*

- **Vast** majority of antibiotics are used by the agricultural sector<sup>1</sup>
- **70%** of bacteria globally has developed some level of resistance to antibiotics<sup>1</sup>
- **10 million**: the number of people who will die every year due to AMR by 2050<sup>2</sup>
- **\$100 trillion**, the estimated total GDP that will be lost globally by 2050 if AMR isn't tackled<sup>2</sup>



# Lead Indication – Pigs

Diarrhoea affects hundreds of millions of piglets born each year



Millions of piglets weaned per year

**20% more piglets die before weaning due to health issues**



# Market Opportunity is clear

- Detach™ addresses a **major need** – the livestock industry need effective alternatives to antibiotics to prevent diarrhoea
- Governments are banning antibiotics for growth promotion and restricting prophylactic use in animal production
- Global animal antibiotic market valued at ~ \$4.6 billion in 2014<sup>1</sup>. Production animals 70%. Pigs lead by market share of 25%.
- Pork is #1 consumed meat in the world
- Global demand for meat is rising. More than 85% more meat needed by 2030<sup>2</sup>.
- Consumers want their meat to be safe
- Retailers are pledging to offer '*antibiotic free*' meat




# Consumer Pressure

## - Food Quality & Food Safety




- McDonald's will stop buying chicken reared on antibiotics used in humans within two years (*March 2015*).
- McDonald's is the largest restaurant chain in the world — this move had a major impact on other retailers and will now affect consumer expectations – and how animals are reared.
- KFC is the latest fast-food chain to move toward a plan to stop serving chicken that has been reared using antibiotics in the U.S. by the end of 2018 (*April 2017*).



# Consumer Pressure

## ConsumerReports<sup>™</sup> meat on drugs

The overuse of antibiotics in food animals & what supermarkets and consumers can do to stop it



ANATARA LIFESCIENCES

# Detach™

- Detach™ is an orally administered **non-antibiotic** alternative
- **Proven efficacy** – evidence-based therapeutic claims
- **Proven safety** – active ingredient is a natural plant based product
- **Broad acting** – acts against a range of causes of diarrhoea
- **Stable** - does not require refrigeration
- Unlike antibiotics, Detach™ will not lead to antimicrobial resistance
- Proven **economic benefits** for farmers
- Peer-reviewed publications in high impact academic journals



# Detach™ - Poised for swift market entry

Commercially validated, supported by demand

- A clear path to market: Launch in 2018
  - Manufacturing complete at commercial scale and global supply confirmed
- Introduction of Detach™ is supported by industry, government, retailer & consumer demand
- Detach™ will be supplied in Australia via pre-existing distribution channels (Australian pork industry is heavily consolidated)
- Focus now is on planning market launch
- Launch in Australia will provide leverage into Asia
- Global partnering interest for worldwide commercialisation



Current 50 kg scale  
(≈500,000 doses)



1,000 kg capacity  
(≈8,500,000 doses)

# What Next?

## Detach™ - A Pipeline in a Product


### **Other Detach™ presentations:**

- Livestock: in-feed
- Livestock: in-water

### **Potential product extensions for the core components of Detach™**


### **Partnering Opportunities for:**

- Human GI conditions (diarrhoea; inflammatory bowel disease; irritable bowel syndrome)



# Detach™ - leverage Pigs to People

Anatara's commercialisation strategy



Detach™  
- From Pigs  
to People

- Same mechanism of action for treatment of disease in pigs and humans
- Pre-clinical program for animals complete therefore development for humans de-risked
- Clinic ready (CMC, Toxicology, Pharmacology well developed)
- Ready to Partner/Develop



# Human GI disorders/disease

## -Large patient populations

1.4 million  
people  
suffering  
in USA

2.3 million  
people  
suffering in  
EU /  
Australia



Inflammatory Bowel Disease is a global issue

**10-15 %**

Percentage of population with  
Irritable Bowel Syndrome

### Traveller's diarrhoea

**50 million**

travellers at risk per year.  
Rising to 100 million by 2020.



TD is a threat to military efficiency  
and preventative treatment is a  
priority for the US Army



### Developing countries

**#2**

cause of death in under 5's  
(1.3 million kids per year.)



### United States of America



~ 211-375m episodes of diarrhoea p.a.  
116m people use anti-diarrhoea medication (31%).

# Anatara Investment Overview

- Experienced board and management team with proven track record
- Lead product, Detach™, has a clear route to market
  - Commercially validated and proven efficacy
  - Development strategy de-risked and revenues within 2 years
- Well funded – sufficient to launch Detach™ in key markets
- Product Pipeline – animal product leads to human product development for partnering opportunities
- Seasoned Operational Team
  - Regulatory, Manufacturing, IP, Clinical Trials, R&D



# Thank you

***“... the unnecessary use of antibiotics in animals and agriculture is a significant concern for human health...”***

***stopping the over-use of antibiotics – fed in vast quantities to animals for growth promotion as well as to treat disease, may be even more important than incentivising the development of new drugs.”***

Lord Jim O'Neill, Chair, Review on Antimicrobial Resistance

Dr Mel Bridges, CEO, Chairman & Co-founder  
mbridges@anataralifesciences.com  
+61 413 051 600

www.anataralifesciences.com  
 @AnataraANR

